![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Even though naratriptan and sumatriptan are both 5-HT1B/5-HT1D receptor agonists, the biological and pharmacokinetic profile of naratriptan differs significantly from that of sumatriptan. With a plasma half-life of 6 h, very high oral bioavailability of 63 - 74% and higher lipophilicity than sumatriptan, naratriptan exhibits a distinct clinical therapeutic profile. The similar tolerability to placebo, prolonged efficacy for 24 h or more and very low headache recurrence rate make naratriptan an attractive option in the treatment of acute migraine.